13F filer · CIK 1633313
Avoro Capital Advisors LLC
NEW YORK, NY · filing since Q4 2014 · last filing Aug 14, 2026
Reported value
$11.1B
+$971.5M vs prior
Positions
26
New / sold out
3 / 9
Added / reduced
11 / 3
Turnover
18.3%
buys $1.9B · sells $2.6B
Top-10 weight
79.5%
Biggest buys vs Q1 2026
| Change | Security | Shares change | Change % | Est. trade value |
|---|---|---|---|---|
| New | ASCENDIS PHARMA | +5,111,111 | – | +$1.4B |
| Added | CYTOKINETICS INC | +1,666,666 | +50.0% | +$142.0M |
| Added | DEFINIUM THERAPEUTICS INC | +2,188,888 | +43.8% | +$103.0M |
| Added | UNITED THERAPEUTICS CORP | +147,777 | +5.6% | +$80.1M |
| New | HEMAB THERAPEUTICS HLDGS INC | +1,925,150 | – | +$70.7M |
| Added | ARROWHEAD PHARMACEUTICALS INC | +655,556 | +6.1% | +$53.4M |
| New | FAETH THERAPEUTICS INC | +1,444,039 | – | +$36.1M |
| Added | UNIQURE NV | +768,182 | +12.9% | +$35.4M |
| Added | VIRIDIAN THERAPEUTICS INC | +1,000,000 | +66.7% | +$18.4M |
| Added | AVALO THERAPEUTICS | +923,333 | +65.5% | +$17.1M |
4 more rows. Subscribe for $29/month to see every row, download the data and use the API.
Biggest sells vs Q1 2026
| Change | Security | Shares change | Change % | Est. trade value |
|---|---|---|---|---|
| Sold out | ASCENDIS PHARMA | -5,062,500 | -100.0% | $-1.2B |
| Sold out | APELLIS PHARMACEUTICALS INC | -12,222,222 | -100.0% | $-491.7M |
| Sold out | CENTESSA PHARMACEUTICALS PLC | -11,430,455 | -100.0% | $-454.0M |
| Sold out | TERNS PHARMACEUTICALS INC | -5,695,000 | -100.0% | $-300.2M |
| Sold out | SOLENO THERAPEUTICS INC | -2,300,000 | -100.0% | $-77.0M |
| Sold out | ALKERMES PLC | -1,200,000 | -100.0% | $-42.4M |
| Sold out | UNITED THERAPEUTICS CORPCALL | -380,000 | -100.0% | $-10.3M |
| Reduced | REVOLUTION MEDICINES INC | -47,444 | -2.0% | $-8.9M |
| Reduced | VERA THERAPEUTICS INC | -165,000 | -2.8% | $-7.1M |
| Sold out | MANNKIND CORP | -2,200,000 | -100.0% | $-5.4M |
2 more rows. Subscribe for $29/month to see every row, download the data and use the API.
Estimated trade value = change in shares × this quarter's implied price. 13F filings show quarter-end positions, not individual trades.
Reported value by quarter
Holdings · Q2 2026
| # | Security | Shares | Value | Weight |
|---|---|---|---|---|
| 1 | UNITED THERAPEUTICS CORPCOMMON | 2,777,777 | $1.5B | 13.52% |
| 2 | ASCENDIS PHARMAORDINARY SHARES | 5,111,111 | $1.4B | 12.24% |
| 3 | KRYSTAL BIOTECH INCCOMMON | 2,888,888 | $1.1B | 9.64% |
| 4 | MADRIGAL PHARMACEUTICALS INCCOMMON | 1,833,333 | $984.4M | 8.84% |
| 5 | ARGENX SESPONSORED ADR | 1,000,000 | $927.8M | 8.33% |
| 6 | ARROWHEAD PHARMACEUTICALS INCCOMMON | 11,355,555 | $925.6M | 8.31% |
| 7 | KYMERA THERAPEUTICS INCCOMMON | 7,474,747 | $857.1M | 7.70% |
| 8 | REVOLUTION MEDICINES INCCOMMON | 2,297,000 | $430.2M | 3.86% |
| 9 | CYTOKINETICS INCCOMMON | 4,999,999 | $425.9M | 3.82% |
| 10 | CELCUITY INCCOMMON | 3,400,000 | $355.7M | 3.19% |
16 more rows. Subscribe for $29/month to see every row, download the data and use the API.